Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +24.11%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.38 per share when it actually produced a loss of $0.36, delivering a surprise of +5.26%.Over the last four quarter ...